Erhard Weidekamm

TL;DR: Capecitabine is a novel fluoropyrimidine carbamate rationally designed to generate 5-fluorouracil preferentially in tumors, which is explained to a great extent by the activity of TP in colorectal tumor tissue, (the enzyme responsible for the conversion of 5′-DFUR to 5-FU), which is approximately four times that in adjacent healthy tissue.

TL;DR: As with other cytotoxic drugs, the interpatient variability of the pharmacokinetic parameters of cape citabine and its metabolites, 5′-deoxy-5-fluorocytidine and fluorouracil, is high and is likely to be primarily due to variability in the activity of the enzymes involved in capecitabine metabolism.

TL;DR: It is recommended that capecitabine be administered with food as this procedure was used in the clinical trials, and a profound influence on Cmax of cape citabine and most of its metabolites was found.

TL;DR: The pharmacokinetics of BAL8557 are well suited to maintaining concentrations of BAL4815 for a long period of time in the body and to enabling an effective treatment of systemic mycoses and based on the exposure data, oral bioavailability of BAL 4815 is assumed to be very high.

TL;DR: Mild to moderate hepatic dysfunction had no clinically significant influence on the pharmacokinetic parameters of capecitabine and its metabolites, and there is no need for, a priori, adjustment of the dose.